PPARD and atherosclerosis: For example, in LDLR KO mice treatment with the PPARβ/δ agonist,GW0742X, was associated with a marked attenuation of atherosclerosis, with aconcomitant decrease in monocyte chemoattractant protein (MCP)-1 andintercellular adhesion molecule (ICAM)-1 [39].